Bluebird Bio Inc. (Nasdaq: BLUE) reported positive preliminary results for its gene therapy treatment LentiGlobin sending the stock price surging $8.37 to close at $34.46.
Bluebird Bio reports upbeat results
June 16, 2014 at 17:08 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.